OpiCalc

989 Clinical Tools

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk Score CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

WHO 2022 AML Classification Mapper

WHO 2022 Updates: Genetic abnormalities now take precedence over blast percentage. AML with mutations like NPM1 or t(8;21) can be diagnosed even if blasts are < 20%.

Select genetic finding to categorize

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Classifying newly diagnosed Acute Myeloid Leukemia (AML) according to the 5th edition of the WHO Classification of Haematolymphoid Tumours.

Integrating cytogenetic and molecular findings with morphological assessment.

Identifying specific "Defined Genetic Abnormalities" that now override the 20% blast threshold.

2022 Revision Key

The 2022 WHO update emphasizes the elimination of the mandatory 20% blast threshold for AML with defining genetic abnormalities (with the exception of BCR::ABL1).

Section 2

Formula & Logic

AML with Defined Genetic Abnormalities

Subtype	Defining Genetic Feature	Notes
AML with promyelocytic (APL)	PML::RARA	Blast threshold not required.
AML with NPM1 mutation	NPM1	Blast threshold not required.
AML with CEBPA mutation	in-frame bZIP mutation	Previously "biallelic," now bZIP-specific.
AML with KMT2A rearrangement	t(11q23.3)	Formerly MLL; blast threshold not required.
AML with RUNX1::RUNX1T1	t(8;21)	Classic favorable risk; threshold not required.
AML with CBFB::MYH11	inv(16) or t(16;16)	Classic favorable risk; threshold not required.

AML, Myelodysplasia-related (AML-MR)

Now defined by specific cytogenetic abnormalities or somatic mutations in genes such as ASXL1, BCOR, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2. Morphological dysplasia alone is no longer sufficient for this category.

Section 3

Pearls/Pitfalls

The 10% Grey Zone

Patients with 10–19% myeloblasts and defining genetic abnormalities (like t(8;21)) are now formally classified as having AML, rather than Myelodysplastic Syndrome (MDS-EB-2).

Therapeutic Pivot

Molecular classification is the primary driver for targeted therapy selection (e.g., FLT3 inhibitors, IDH1/2 inhibitors, or CPX-351 for AML-MR).

Section 4

Evidence Appraisal

Primary Strategy

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Khoury JD et al. • Leukemia. 2022;36(7):1703-1719.

View Source

Comparison of the WHO 2022 and ICC 2022 classifications of AML.

Daver N et al. • Blood Reviews. 2023;Analysis of concordances and differences.

View Source

Section 5

Literature

Nomenclature

Developed through an international consensus of hematopathologists and clinicians to replace the 2016 4th Revised Edition.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Classifying newly diagnosed Acute Myeloid Leukemia (AML) according to the 5th edition of the WHO Classification of Haematolymphoid Tumours.

Integrating cytogenetic and molecular findings with morphological assessment.

Identifying specific "Defined Genetic Abnormalities" that now override the 20% blast threshold.

2022 Revision Key

The 2022 WHO update emphasizes the elimination of the mandatory 20% blast threshold for AML with defining genetic abnormalities (with the exception of BCR::ABL1).

Section 2

Formula & Logic

AML with Defined Genetic Abnormalities

Subtype	Defining Genetic Feature	Notes
AML with promyelocytic (APL)	PML::RARA	Blast threshold not required.
AML with NPM1 mutation	NPM1	Blast threshold not required.
AML with CEBPA mutation	in-frame bZIP mutation	Previously "biallelic," now bZIP-specific.
AML with KMT2A rearrangement	t(11q23.3)	Formerly MLL; blast threshold not required.
AML with RUNX1::RUNX1T1	t(8;21)	Classic favorable risk; threshold not required.
AML with CBFB::MYH11	inv(16) or t(16;16)	Classic favorable risk; threshold not required.

AML, Myelodysplasia-related (AML-MR)

Section 3

Pearls/Pitfalls

The 10% Grey Zone

Patients with 10–19% myeloblasts and defining genetic abnormalities (like t(8;21)) are now formally classified as having AML, rather than Myelodysplastic Syndrome (MDS-EB-2).

Therapeutic Pivot

Molecular classification is the primary driver for targeted therapy selection (e.g., FLT3 inhibitors, IDH1/2 inhibitors, or CPX-351 for AML-MR).

Section 4

Evidence Appraisal

Primary Strategy

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Khoury JD et al. • Leukemia. 2022;36(7):1703-1719.

View Source

Comparison of the WHO 2022 and ICC 2022 classifications of AML.

Daver N et al. • Blood Reviews. 2023;Analysis of concordances and differences.

View Source

Section 5

Literature

Nomenclature

Developed through an international consensus of hematopathologists and clinicians to replace the 2016 4th Revised Edition.

Last Comprehensive Review: 2026

Related Hematology Tools

Age-adjusted D-dimer Threshold

sPESI

HEP Score

HERDOO2 Rule

Vienna Prediction Model

Padua RAM

Have feedback about this calculator?Let us know.

WHO 2022 AML Classification Mapper

WHO 2022 Updates: Genetic abnormalities now take precedence over blast percentage. AML with mutations like NPM1 or t(8;21) can be diagnosed even if blasts are < 20%.

Select genetic finding to categorize

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Classifying newly diagnosed Acute Myeloid Leukemia (AML) according to the 5th edition of the WHO Classification of Haematolymphoid Tumours.

Integrating cytogenetic and molecular findings with morphological assessment.

Identifying specific "Defined Genetic Abnormalities" that now override the 20% blast threshold.

2022 Revision Key

The 2022 WHO update emphasizes the elimination of the mandatory 20% blast threshold for AML with defining genetic abnormalities (with the exception of BCR::ABL1).

Section 2

Formula & Logic

AML with Defined Genetic Abnormalities

Subtype	Defining Genetic Feature	Notes
AML with promyelocytic (APL)	PML::RARA	Blast threshold not required.
AML with NPM1 mutation	NPM1	Blast threshold not required.
AML with CEBPA mutation	in-frame bZIP mutation	Previously "biallelic," now bZIP-specific.
AML with KMT2A rearrangement	t(11q23.3)	Formerly MLL; blast threshold not required.
AML with RUNX1::RUNX1T1	t(8;21)	Classic favorable risk; threshold not required.
AML with CBFB::MYH11	inv(16) or t(16;16)	Classic favorable risk; threshold not required.

AML, Myelodysplasia-related (AML-MR)

Section 3

Pearls/Pitfalls

The 10% Grey Zone

Patients with 10–19% myeloblasts and defining genetic abnormalities (like t(8;21)) are now formally classified as having AML, rather than Myelodysplastic Syndrome (MDS-EB-2).

Therapeutic Pivot

Molecular classification is the primary driver for targeted therapy selection (e.g., FLT3 inhibitors, IDH1/2 inhibitors, or CPX-351 for AML-MR).

Section 4

Evidence Appraisal

Primary Strategy

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Khoury JD et al. • Leukemia. 2022;36(7):1703-1719.

View Source

Comparison of the WHO 2022 and ICC 2022 classifications of AML.

Daver N et al. • Blood Reviews. 2023;Analysis of concordances and differences.

View Source

Section 5

Literature

Nomenclature

Developed through an international consensus of hematopathologists and clinicians to replace the 2016 4th Revised Edition.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Classifying newly diagnosed Acute Myeloid Leukemia (AML) according to the 5th edition of the WHO Classification of Haematolymphoid Tumours.

Integrating cytogenetic and molecular findings with morphological assessment.

Identifying specific "Defined Genetic Abnormalities" that now override the 20% blast threshold.

2022 Revision Key

The 2022 WHO update emphasizes the elimination of the mandatory 20% blast threshold for AML with defining genetic abnormalities (with the exception of BCR::ABL1).

Section 2

Formula & Logic

AML with Defined Genetic Abnormalities

Subtype	Defining Genetic Feature	Notes
AML with promyelocytic (APL)	PML::RARA	Blast threshold not required.
AML with NPM1 mutation	NPM1	Blast threshold not required.
AML with CEBPA mutation	in-frame bZIP mutation	Previously "biallelic," now bZIP-specific.
AML with KMT2A rearrangement	t(11q23.3)	Formerly MLL; blast threshold not required.
AML with RUNX1::RUNX1T1	t(8;21)	Classic favorable risk; threshold not required.
AML with CBFB::MYH11	inv(16) or t(16;16)	Classic favorable risk; threshold not required.

AML, Myelodysplasia-related (AML-MR)

Section 3

Pearls/Pitfalls

The 10% Grey Zone

Patients with 10–19% myeloblasts and defining genetic abnormalities (like t(8;21)) are now formally classified as having AML, rather than Myelodysplastic Syndrome (MDS-EB-2).